Dual GIP/GLP-1 Research
Research on tirzepatide's dual GIP and GLP-1 receptor agonism mechanisms.
Dual GIP/GLP-1 Receptor Research
Tirzepatide (GLP-2 T) is the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Its unique dual mechanism has generated significant research interest.
GIP Receptor Biology
The GIP receptor is expressed in adipose tissue, bone, brain, and pancreatic beta cells. GIP's role in fat storage vs. fat mobilization has been debated, but research suggests GIP receptor agonism in the context of GLP-1 co-stimulation produces beneficial metabolic effects:
- Enhanced insulin secretion beyond GLP-1 alone
- Potential adipocyte lipolysis stimulation
- Brown adipose tissue thermogenesis activation
- GLP-1 receptor sensitization
Synergistic Effects
The combination of GIP + GLP-1 receptor activation appears synergistic rather than merely additive. Research proposes that GIP receptor agonism may: 1. Potentiate GLP-1 receptor signaling in beta cells 2. Provide independent metabolic effects via adipocyte GIPR 3. Enhance nutrient-stimulated insulin secretion through dual incretin pathways
Structural Features
Tirzepatide is a 39-amino acid peptide based on native GIP sequence with:
- Aib at position 2: DPP-4 resistance
- C20 fatty diacid at Lys26: Extended half-life (~5 days)
- Selective modifications for dual receptor activity
Research-Grade Dual GIP/GLP-1 Research
>98% purity, third-party tested. Free shipping on orders over $200.
Dual GIP/GLP-1 Research — Available Products
Research-grade compounds. >98% purity, CoA available on request.
GLP-2 T 15mg
Tirzepatide dual GIP/GLP-1 receptor agonist, 39 amino acids with C20 lipidation. Supplied as lyophilized powder for laboratory research applications.
CAS: 2023788-19-2
Frequently Asked Questions
What receptors does tirzepatide target?
Tirzepatide targets both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It has higher affinity for GIPR than GLP-1R, unlike native GIP which has equal incretin activity.
How is tirzepatide different from semaglutide?
Semaglutide is a single GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. This dual mechanism produced greater weight loss in SURMOUNT-1 (22.5%) vs STEP-1 semaglutide (14.9%).
What is the half-life of tirzepatide?
Tirzepatide has a half-life of approximately 5 days, enabling once-weekly dosing in research protocols.
Research-Grade Dual GIP/GLP-1 Research
Third-party tested, >98% purity guaranteed. For legitimate scientific research.